Trial Profile
EFFECTS OF SITAGLIPTIN THERAPY ON THE KINETICS OF MARKERS OF LOW-GRADE INFLAMMATION AND CELL ADHESION MOLECULES IN PATIENTS WITH TYPE 2 DIABETES
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 11 Mar 2019 Status changed from active, no longer recruiting to completed.
- 03 May 2017 Planned End Date changed from 1 Mar 2017 to 31 Mar 2018.
- 03 May 2017 Planned primary completion date changed from 1 Feb 2017 to 30 Sep 2017.